Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9104259 | 0.87 | FDPS (0.39) | FDPS | |
| SCHEMBL27554271 | 0.78 | FDPS (0.47) | FDPSHDAC1HDAC6 | |
| SCHEMBL29139986 | 0.78 | FDPS (0.47) | FDPSHDAC1HDAC6 | |
| SCHEMBL5989432 | 0.78 | FDPS (0.51) | FDPSHDAC1HDAC6 | |
| SCHEMBL595230 | 0.77 | FDPS (0.46) | FDPSHDAC1HDAC6 | |
| SCHEMBL28139965 | 0.72 | FGFR1 (0.43) | FDPS | |
| SCHEMBL2676961 | 0.72 | FDPS (0.44) | FDPSHDAC1HDAC6 | |
| SCHEMBL28272 | 0.72 | FDPS (0.44) | FDPSHDAC1HDAC6 | |
| SCHEMBL13857852 | 0.70 | FDPS (0.41) | FDPSHDAC1HDAC6 | |
| SCHEMBL13281305 | 0.66 | FDPS (0.41) | FDPSHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012078416-A2 | MONOPHOSPHATE PRODRUGS OF DAPD AND ANALOGS THEREOF | RFS PHARMA, LLC (US) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142627-A1 | MONOPHOSPHATE PRODRUGS OF DAPD AND ANALOGS THEREOF | EMORY UNIVERSITY (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142627-A1 | MONOPHOSPHATE PRODRUGS OF DAPD AND ANALOGS THEREOF | DCTD, ENTPD5, PNP | FDPS 99/4885HDAC1 3437/4885HDAC6 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.